moneyheap
TAK · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) stock moving?
Takeda's fiscal first-half results, released Oct 29, 2026, were the main recent catalyst. Revenue rose 8.4% to JPY 2,406,997M, operating profit rose 60.4%, and net profit attributable to owners rose 171.8% to JPY 305,626M (basic EPS JPY 192.53). Q2 adjusted EPS of $0.48 beat the $0.31 estimate, sales of $7.457B beat the $7.190B estimate, and management raised FY2026 core EPS guidance to JPY 482 (from JPY 472), revenue guidance to JPY 4,700B (from JPY 4,640B), and GAAP EPS guidance to JPY 131 (from JPY 104). The main risk named in coverage is the generic overhang from off-patent Vyvanse. Price action was muted on the day: the stock traded down to a 19.50 low on 4.81M shares and closed at 20.01. It then rallied 4.5% to 20.91 on Oct 30 with 4.63M shares. Since then it has traded mostly between 20.6 and 21.2 on closes, with intraday highs of 21.22 (Oct 30) and 21.73 (Nov 5). The latest close was 20.93 on Nov 10, on 2.95M shares, close to the middle of that range. Volume has normalised after the earnings spikes, and no new company-specific catalyst appeared in the news window. The earnings-driven upgrade is still the main support for the outlook, but most of the reaction has already played out.
News behind the analysis
- Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic OverhangTakeda beat Q2 estimates and raised its fiscal 2026 outlook, with pipeline growth and cost cuts offsetting off-patent Vyvanse losses.
- Takeda Pharmaceutical Q2 Adj. EPS $0.48 Beats $0.31 Estimate, Sales $7.457B Beat $7.190B EstimateAdjusted Q2 EPS of $0.48 topped the $0.31 consensus, and sales of $7.457B beat the $7.190B estimate.
- Takeda Pharmaceutical Co Raises FY2026 Core EPS Guidance from JPY 472 to JPY 482; Raises FY2026 Revenue Guidance from JPY 4,640B to JPY 4,700BTakeda raised its FY2026 core EPS guidance to JPY 482 from JPY 472 and its revenue guidance to JPY 4,700B from JPY 4,640B.
- Takeda Pharmaceutical Co Raises FY2026 GAAP EPS Guidance from JPY 104 to JPY 131Takeda lifted its FY2026 GAAP EPS guidance to JPY 131 from JPY 104.
- Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline MilestonesTakeda reported first-half FY2026 results, highlighting key product launches and pipeline progress.
- Takeda Pharmaceutical Co Q2 2026 Earnings Call TranscriptTranscript of the Q2 2026 earnings call, held on the day Takeda reported second-quarter results.
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is Japan's largest drugmaker, based in Tokyo and Osaka. It sells medicines worldwide, with most of its sales in the US, and focuses on gut diseases, rare diseases, plasma-derived therapies, cancer, neuroscience and vaccines. Its US shares trade on the NYSE as ADRs, and each ADR equals half of one Tokyo-listed share.
How it makes money
It earns money by selling prescription drugs. Core revenue for the fiscal year ended March 2026 was about ¥4.5 trillion (roughly $28 billion). About half of that came from 'growth and launch' products, such as the gut-disease drug Entyvio, the rare-disease drug Takhzyro and plasma-derived immunoglobulin and albumin. The rest came from older brands, including the ADHD drug Vyvanse, whose sales are falling because of generic copies. Newer drugs, such as the narcolepsy treatment Orzeyful (oveporexton, approved by the FDA in 2026) and the experimental psoriasis pill zasocitinib, are expected to add revenue.
What usually moves TAK
- Entyvio and plasma-therapy sales growth
- Vyvanse and other generic erosion
- New launches (oveporexton, rusfertide, zasocitinib)
- Yen–dollar exchange rate
- Litigation and US drug-pricing policy